Advert - AstraZeneca – Case AUTH/3774/6/23

• Date posted
  17 February 2025
• Sanction
  Advertisement,
• Case number/s
  AUTH/3774/6/23 – Complainant v AstraZeneca

For promoting durvalumab outside of the terms of its marketing authorisation and promoting tremelimumab prior to the grant of its marketing authorisation by interacting with two LinkedIn posts, and the impression created by very senior staff acting contrary to the company’s global social media policy, AstraZeneca was ruled in breach of the following clauses of the 2019 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.1 - Promoting a medicine prior to the grant of the marketing authorisation

Clause 9.1 - Failing to maintain high standards

Clause 26.1 - Promoting a prescription only medicine to the public